Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01188031 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01188031 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 40 participants.
The verdict
NCT01188031, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study compared the relative bioavailability (rate and extent ofbsorption) of Alprazolam Orally Disintegrating Tablets, 2.0 mg by Purepac Pharmaceutical Co. with that of Niravam' 2 mg Orally Disintegrating Tablets manufactured for Schwarz Pharma, Inc. (by Cima Labs Inc.®)following a single, oral dose (I x 2 mg disintegrating tablet) in healthy adult volunteers administered under fasting conditions.
Interventions
- DRUG ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG
- DRUG NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-06 |
| Est. Completion | 2006-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01188031
The ClinicalTrials.gov registry entry for NCT01188031 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG is the first listed.
NCT01188031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01188031 about?
NCT01188031 is a clinical study titled "A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions". This study compared the relative bioavailability (rate and extent ofbsorption) of Alprazolam Orally Disintegrating Tablets, 2.0 mg by Purepac Pharmaceutical Co. with that of Niravam' 2 mg Orally Disintegrating Tablets manufactured for Schwarz Pharma, Inc. (by Cima Labs Inc.®)following a single, oral...
What is the current status of trial NCT01188031?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-06. Estimated completion is 2006-07.
What interventions are being tested in trial NCT01188031?
The interventions under investigation include: ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG (DRUG), NIRAVAM TM 2 mg orally disintegrating tablets, single dose (DRUG).
Who is sponsoring clinical trial NCT01188031?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.